Attention deficit/hyperactivity disorder (ADHD) is a neurodevelopmental disorder characterized by the presence of impairing levels of inattention, disorganization and/or hyperactivity-impulsivity.
Symptoms that suggest ADHD include hyperactivity, acting without thinking, inattention/daydreaming, fidgety, restless, excessive talking, aggressive behavior, academic underachievement, disorganized and has difficulty in completing tasks.
Once-daily treatment with viloxazine extended release, also known as SPN-812, is safe and effective in children aged 6–11 years with attention-deficit/hyperactivity disorder (ADHD), yielding rapid improvements in symptoms and function, according to the results of a phase III trial.
Use of the prescription stimulant methylphenidate appears to also exert a positive effect on the lower urinary tract in children with attention deficit hyperactivity disorder (ADHD) but without voiding dysfunction, specifically increasing voided volume and bladder capacity, as shown in a study.
There is a high incidence of psychiatric comorbidities among gender nonconforming teenagers, with about two-thirds and one-third experiencing depression and anxiety, respectively, according to a study presented at ENDO 2020.
Adolescents with attention-deficit/hyperactivity disorder (ADHD) are likely to consume a greater amount of caffeine during later times of the day, which, in turn, is associated with sleep problems, a study has found.
Individuals with attention-deficit hyperactivity disorder (ADHD) are likely to exhibit suicidal behaviour, and this probability is further increased in the presence of comorbid psychiatric disorders, a recent study suggests.
An 8-week attention training programme using brain-computer interface (BCI) can help improve inattentive symptoms in children with attention deficit hyperactivity disorder (ADHD), thus providing a potential nonpharmacologic option for treating ADHD, a local study finds.
A novel device for trigeminal nerve stimulation (TNS) effectively improves attention deficit hyperactivity disorder (ADHD) symptoms in children aged 8–12 years, providing a safe nonmedication approach to treating ADHD, a recent study shows.
Use of memantine in the treatment of adults with attention deficit hyperactivity disorder (ADHD) appears to reduce symptoms associated with the condition, in addition to having a tolerable safety profile, a study has shown.
Dr. Hsu Li Yang, Dr. Tan Thuan Tong, Dr. Andrea Kwa,
08 Jan 2021
Antimicrobial resistance has become increasingly dire as the rapid emergence of drug resistance, especially gram-negative pathogens, has outpaced the development of new antibiotics. At a recent virtual symposium, Dr Hsu Li Yang, Vice Dean (Global Health) and Programme Leader (Infectious Diseases), NUS Saw Swee Hock School of Public Health, presented epidemiological data on multidrug-resistant (MDR) gram-negative bacteria (GNB) in Asia, while Dr Tan Thuan Tong, Head and Senior Consultant, Department of Infectious Diseases, Singapore General Hospital (SGH), focused on the role of ceftazidime-avibactam in MDR GNB infections. Dr Andrea Kwa, Assistant Director of Research, Department of Pharmacy, SGH, joined the panel in an interactive fireside chat, to discuss challenges, practical considerations, and solutions in MDR gram-negative infections. This Pfizer-sponsored symposium was chaired by Dr Ng Shin Yi, Head and Senior Consultant of Surgical Intensive Care, SGH.